Cantor Fitzgerald Reduces Earnings Estimates for Mesoblast

Mesoblast Limited (NASDAQ:MESO) – Equities research analysts at Cantor Fitzgerald lowered their FY2025 earnings per share (EPS) estimates for Mesoblast in a research note issued to investors on Monday, March 31st. Cantor Fitzgerald analyst K. Kluska now expects that the company will post earnings of ($0.71) per share for the year, down from their previous forecast of ($0.70). Cantor Fitzgerald currently has a “Strong-Buy” rating on the stock. The consensus estimate for Mesoblast’s current full-year earnings is ($0.70) per share.

MESO has been the subject of several other research reports. Jefferies Financial Group downgraded shares of Mesoblast from a “buy” rating to a “hold” rating in a report on Monday, December 23rd. Piper Sandler reiterated an “overweight” rating and issued a $24.00 price objective (up previously from $15.00) on shares of Mesoblast in a research note on Friday, February 7th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $18.00.

Mesoblast Price Performance

Shares of NASDAQ:MESO opened at $11.82 on Wednesday. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.18 and a current ratio of 1.18. The stock’s fifty day simple moving average is $15.97 and its two-hundred day simple moving average is $13.28. Mesoblast has a 1-year low of $4.60 and a 1-year high of $22.00.

Institutional Investors Weigh In On Mesoblast

Hedge funds have recently made changes to their positions in the business. Jane Street Group LLC increased its holdings in Mesoblast by 46.4% during the third quarter. Jane Street Group LLC now owns 85,102 shares of the company’s stock worth $695,000 after buying an additional 26,959 shares during the last quarter. GAMMA Investing LLC grew its position in shares of Mesoblast by 22.1% during the 4th quarter. GAMMA Investing LLC now owns 6,711 shares of the company’s stock valued at $133,000 after acquiring an additional 1,213 shares during the period. Ballentine Partners LLC purchased a new stake in shares of Mesoblast during the 4th quarter worth approximately $222,000. R Squared Ltd purchased a new stake in shares of Mesoblast during the 4th quarter worth approximately $30,000. Finally, China Universal Asset Management Co. Ltd. bought a new stake in shares of Mesoblast in the 4th quarter worth approximately $134,000. 1.43% of the stock is currently owned by institutional investors.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.